SCRI Development Innovations, LLC: Lung Neoplasms trials

The registry lists 35 Lung Neoplasms studies with SCRI Development Innovations, LLC as lead sponsor. 0 are open to participants now and 21 have results posted.

Phase 1 1Phase 2 32Phase 3 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung CancerCompletedNCT01829113Phase 2Results posted
• Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to ErlotinibCompletedNCT01487265Phase 2Results posted
• A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung CancerCompletedNCT01076504Phase 2Results posted
• Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLCCompletedNCT01042288Phase 2Results posted
• Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung CancerCompletedNCT01027598Phase 2Results posted
• Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLCTerminatedNCT00960297Phase 2Results posted
• Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung CancerCompletedNCT00906282Phase 2Results posted
• Trial of Poor Performance Status Patients (ToPPS)CompletedNCT00892710Phase 2Results posted
• Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung CancerCompletedNCT00741988Phase 2Results posted
• Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung CancerCompletedNCT00695292Phase 2Results posted
• Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLCCompletedNCT00621049Phase 2Results posted
• Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on ErlotinibCompletedNCT00609804Phase 2Results posted
• Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)CompletedNCT00600015Phase 2Results posted
• First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLCCompletedNCT00456261Phase 2Results posted
• Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung CancerTerminatedNCT00402883Phase 2Results posted
• Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung CancerCompletedNCT00305942Phase 2Results posted
• Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung CancerCompletedNCT00284154Phase 2Results posted
• Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung CancerCompletedNCT00193453Phase 2Results posted
• Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung CancerCompletedNCT00193427Phase 2Results posted
• Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00193414Phase 2Results posted
• Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung CancerCompletedNCT00193375Phase 2Results posted
• Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent LorlatinibWithdrawnNCT05948462Phase 2
• LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic MalignanciesTerminatedNCT02649673Phase 1
• Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or LongerCompletedNCT01522833
• Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung CancerCompletedNCT00308529Phase 2
• Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung CancerCompletedNCT00294931Phase 2
• Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung CancerCompletedNCT00294190Phase 2
• Weekly Topotecan in the First-line Treatment of Elderly Patients With Small Cell Lung CancerCompletedNCT00193401Phase 2
• Weekly Topotecan in the Second-Line Treatment of Small Cell Lung CancerCompletedNCT00193388Phase 2
• Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung CancerCompletedNCT00193362Phase 3
• Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung CancerCompletedNCT00193349Phase 2
• Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung CancerCompletedNCT00193336Phase 2
• Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly PatientsCompletedNCT00193323Phase 2
• Preoperative or Postoperative Therapy of Patients With Stages IB, II, IIIA Non-Small Cell Lung CancerCompletedNCT00193310Phase 2
• Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung CancerCompletedNCT00193245Phase 2